Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05124886 · ClinicalTrials.gov registry record · NA
Gut Kidney Axis in Enteric Hyperoxaluria
A NA study of Enteric Hyperoxaluria, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT05124886: Recruiting NA study of Enteric Hyperoxaluria, sponsored by NYU Langone Health.
NCT05124886 is a NA study of Enteric Hyperoxaluria that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 80 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05124886, a NA study of Enteric Hyperoxaluria, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
40 subjects with a confirmed diagnosis of IBD or \>6 months post-RYGB with a diagnosed USD event or kidney stone on imaging within the past three years and 40 healthy controls will be administered a high oxalate diet on Days 0-3 and Days 21-24 with a washout period on Days 4-7 and will be administered 250mg sodium oxalate on Days 8-20, via prepared spinach, from Weil Cornell Medicine's Clinical and Translational Science Center. Subjects will partake in four stool collections, four 24-h urine collections, two blood collections, and four sets of colonic permeability testing.
Primary Outcome
UOx will be quantified in 24-h samples
Conditions Studied
Interventions
- OTHER Moderately High Oxalate (MOx) Diet
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2022-11-10 |
| Est. Completion | 2026-03-01 |
| Phase | NA |
What NCT05124886 shows while recruiting
NCT05124886 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Enteric Hyperoxaluria appearing as the primary indexed condition, and to 1 intervention - of which Moderately High Oxalate (MOx) Diet is the first listed.
NCT05124886 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05124886 about?
NCT05124886 is a clinical study titled "Gut Kidney Axis in Enteric Hyperoxaluria". 40 subjects with a confirmed diagnosis of IBD or \>6 months post-RYGB with a diagnosed USD event or kidney stone on imaging within the past three years and 40 healthy controls will be administered a high oxalate diet on Days 0-3 and Days 21-24 with a washout period on Days 4-7 and will be administer...
What is the current status of trial NCT05124886?
This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2022-11-10. Estimated completion is 2026-03-01.
What conditions does trial NCT05124886 study?
This clinical trial studies the following conditions: Enteric Hyperoxaluria.
What interventions are being tested in trial NCT05124886?
The interventions under investigation include: Moderately High Oxalate (MOx) Diet (OTHER).
Who is sponsoring clinical trial NCT05124886?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05124886 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Enteric Hyperoxaluria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05124886's enrollment target sits among peer trials
80 995th of 2000 higher than 941 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI